Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

The Mochudi Prevention Project ART Protocol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01583439
Recruitment Status : Terminated (Low Accrual.)
First Posted : April 24, 2012
Last Update Posted : March 19, 2015
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Max Essex, Harvard School of Public Health

Tracking Information
First Submitted Date  ICMJE April 11, 2012
First Posted Date  ICMJE April 24, 2012
Last Update Posted Date March 19, 2015
Study Start Date  ICMJE September 2012
Actual Primary Completion Date February 2013   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 23, 2012)
  • The proportion of individuals with CD4≥250 cells/mm3 and VL≥50,000 cp/mL who start 3-drug ART
  • The proportion of patients experiencing Grade 3 or 4 clinical or laboratory adverse events by the end of follow-up
  • The proportion of participants with excellent adherence (defined as participant self-report of taking at least 95% of doses of antiretrovirals during the previous 4 days, on all assessments) by the end of follow-up
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT01583439 on Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: April 23, 2012)
  • Presence of ARV drug resistance at time of virologic failure on first- and second-line treatment, among participants experiencing virologic failure
  • Time to first opportunistic infections
  • Time to death
  • Time to first episode of non-adherence: the first episode of non-adherence will be the report of the failure of a patient to take 95% of prescribed pills, or participant self-discontinuation of antiretrovirals.
  • Motivation for / barriers to acceptance of ART will be analyzed descriptively
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE The Mochudi Prevention Project ART Protocol
Official Title  ICMJE An Evaluation of the Uptake and Safety of, and Adherence to Antiretroviral Treatment Among Individuals With CD4 ≥ 250 Cells/mm3 and HIV Virus Load ≥ 50,000 cp/mL
Brief Summary The goal of the "Mochudi Prevention Project" is to reduce the number of new HIV infections in the village of Mochudi, Botswana by promoting a comprehensive package of interventions that have proven to be effective in preventing the spread of HIV. This antiretroviral treatment (ART) clinical study is nested within the Mochudi Prevention Project, and is being conducted in the north-east segment (NES) of the village of Mochudi. The ART intervention component of the Mochudi Project is designed to determine the uptake of, adherence to, and feasibility of 3-drug combination ART as a component of a package of transmission prevention strategies. The hypotheses are 1) that ART (with 3 antiretrovirals from two classes of drugs) among participants with CD4 ≥ 250 cells/mm3 and VL ≥ 50,000 cp/mL will be acceptable and safe and 2) Eighty percent of eligible participants will agree to start 3-drug ART.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE HIV Infections
Intervention  ICMJE Drug: highly active antiretroviral therapy: Lopinavir/Ritonavir, Lamivudine, Zidovudine, Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine
Atripla: one tablet administered orally once daily at bedtime, each tablet comprised of co-formulated: Efavirenz (EFV) 600mg, Emtricitabine (FTC) 200mg, Tenofovir disoproxil fumarate (TDF) 300mg(EFV/FTC/TDF). Note: the study will generally provide the fixed-dose combination Atripla, but it will also be permissible for the same drugs to be used at the same doses as individual components (or as Truvada, coformulated TDF/FTC). Other drug substitutions may be made per the protocol.
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: May 17, 2013)
Original Estimated Enrollment  ICMJE
 (submitted: April 23, 2012)
Actual Study Completion Date  ICMJE September 2013
Actual Primary Completion Date February 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • HIV-1 infection
  • CD4 cell count ≥ 250 cells/mm3
  • HIV-1 RNA ≥ 50,000 cp/mL
  • No AIDS-defining illness or other illness that would cause volunteer to be eligible for ART through the Botswana National Program (these volunteers should be referred to the National Program for treatment)
  • Age 16 to 64 years
  • Botswana citizen
  • Resident of the north-east segment of Mochudi
  • The following laboratory values obtained within 60 days prior to study enrollment:

    • Absolute neutrophil count (ANC) ≥ 500 cells/mm3.
    • Hemoglobin ≥ 7.0 g/dL.
    • AST (SGOT), ALT (SGPT), and bilirubin ≤ 5 X ULN. Note: if the estimated creatinine clearance (by Cockgroft-Gault equation) is <60 mL/min, then TDF/FTC will be substituted with ZDV/3TC
  • Ability to swallow oral medications.
  • Ability and willingness of participant to give informed consent (or in case of participants < 18 years of age, ability and willingness to provide assent; and for parent/guardian to provide consent).
  • Not currently involuntarily incarcerated.
  • Karnofsky performance score ≥ 70 at time of study enrollment.
  • If participating in sexual activity that could lead to pregnancy and of reproductive potential, female participants must use two reliable methods of contraception simultaneously, one of which must be a barrier method, while receiving protocol-specified medications, and for 12 weeks after stopping the medications.
  • For participants < 18 years of age: Weight of 40kg or more

Exclusion Criteria:

  • Receipt at any time prior to study enrollment of > 7 days cumulative treatment with any ARV or combination of ARVs (except ARVs taken for any length of time during pregnancy for the prevention of mother-to-child transmission (pMTCT) or ARVs taken for occupational exposure).
  • Current receipt of 3-drug ART for pMTCT
  • Allergy/sensitivity to any study drug or its formulations.
  • Acute therapy for serious medical illnesses, in the opinion of the site investigator, within 14 days prior to enrollment.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 16 Years to 64 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Botswana
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT01583439
Other Study ID Numbers  ICMJE BHP041
R01AI083036 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Max Essex, Harvard School of Public Health
Study Sponsor  ICMJE Harvard School of Public Health
Collaborators  ICMJE National Institute of Allergy and Infectious Diseases (NIAID)
Investigators  ICMJE
Principal Investigator: Max Essex, DVM, PhD Harvard School of Public Health
Principal Investigator: Victor DeGruttola, S.M., Sc.D. Harvard School of Public Health
PRS Account Harvard School of Public Health
Verification Date March 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP